Online inquiry

IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8177MR)

This product GTTS-WQ8177MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FCGRT gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8177MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5285MR IVTScrip™ mRNA-Anti-IL4-α, CD124(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CD124
GTTS-WQ995MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-383
GTTS-WQ6636MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DI-17E6
GTTS-WQ11614MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, MGD-006(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MGD-006
GTTS-WQ4462MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-901608
GTTS-WQ4885MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ6723MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DS 1024
GTTS-WQ13019MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW